



PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/689,235
	Filing Date	October 20, 2003
	First Named Inventor	Dermatakis et al.
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21269 US1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks -References B1-B6, and C1-C3; & Co-pending application USSN. 10/697,543	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual	Patricia S. Rocha-Tramaloni	
Signature		
Date	January 15, 2004	

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date January 15, 2004			
Typed or printed	Patricia S. Rocha-Tramaloni		
Signature		Date	January 15, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Dermatakis et al.

Serial No. 10/689,235, filed October 20, 2003
(Ref. No. 21269 US1)

For: **PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY**

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
January 15, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1-B6, and C1-C3 listed on Form PTO-1449 are enclosed.
Document A1 is not being submitted because it is a US patent.

Serial No. 10/689,235
Filed: October 20, 2003

The Examiner's attention is also directed to co-pending application US Serial No. 10/697,543 (CD 21454 US) filed in the US on October 30, 2003, a copy of which is enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.


Respectfully submitted,



Attorney for Applicant(s)
Patricia S. Rocha-Tramaloni
(Reg. No. 31,054)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-2441
Telefax: (973) 235-2363

Attachments

137905



Substitute for form 1449A/PTO					Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Application Number	10/689,235	
					Filing Date	October 20, 2003	
					First Name Inventor	Dermatakis, et al.	
(Use several sheets if necessary)					Attorney Docket Number	21269 US1	
Sheet	1	of	1				
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
	A1	6,150,373		Harris, et al.	11/21/2000		
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B1	WO 03/062236			Warner Lambert Co. LLC	07/31/2003	
	B2	WO 98/24432			Sugen, Inc.	06/11/1998	
	B3	WO 99/61444			Warner Lambert Co.	12/02/1999	
	B4	WO 01/29041			F.Hoffmann-La Roche AG	04/26/2001	
	B5	WO 01/29042			F.Hoffmann-La Roche AG	04/26/2001	
	B6	WO 01/64679			Smithkline Beecham Corp.	09/07/2001	
NON PATENT LITERATURE DOCUMENTS							
	C1	Hennequin L. F. et al., J. Med. Chem. 2002, Vol. 45(6) pgs. 1300-1312					
	C2	Klohs W. E. et al., Current Opinion in Biotechnology, 1999 Vol. 10, pgs. 544-549					
	C3	D. H. Boschelli & F. Boschelli, Drugs of the Future, 2000 25(7) pgs. 717-736					
Examiner Signature		Date Considered					

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation or abstract is attached.

137909